Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
Metrics: PDF 2747 views | HTML 2794 views | ?
Masaki Shiota1, Jennifer L. Bishop1, Ario Takeuchi1, Ka Mun Nip1, Thomas Cordonnier1, Eliana Beraldi1, Hidetoshi Kuruma1, Martin E. Gleave1,2 and Amina Zoubeidi1,2
1 The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
2 Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
Amina Zoubeidi, email:
Keywords: enzalutamide, HER2, castration resistant prostate cancer, lapatinib
Received: January 03, 2015 Accepted: February 12, 2015 Published: March 15, 2015
Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR) activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are mainstay treatments for CRPC; however patients eventually progress with ENZ resistant (ENZR) disease. In this study, we investigated one mechanism of ENZ resistance, and tried to improve therapeutic efficiency of ENZ. We found HER2 expression is increased in ENZR tumors and cell lines, and is induced by ENZ treatment of LNCaP cells. ENZ-induced HER2 overexpression was dependent on AKT-YB1 activation and modulated AR activity. HER2 dependent AR activation in LNCaP and ENZR cells was effectively blocked by treatment with the EGFR/HER2 inhibitor Lapatinib, which reduced cell viability and increased apoptosis. Despite efficacy in vitro, in vivo monotherapy with Lapatinib did not prevent ENZR tumor growth. However, combination treatment of Lapatinib with ENZ most effectively induced cell death in LNCaP cells in vitro and was more effective than ENZ alone in preventing tumor growth in an in vivo model of CRPC. These results suggest that while HER2 overexpression and subsequent AR activation is a targetable mechanism of resistance to ENZ, therapy using Lapatinib is only a rational therapeutic approach when used in combination with ENZ in CRPC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.